Story perspectives
FDA Flags Novo Nordisk Plant; Eli Lilly's Orforglipron Shines
10/18/2025
1 of 1
Story summary
- Eli Lilly's oral GLP-1 receptor agonist orforglipron draws attention as the Food and Drug Administration designates Novo Nordisk's Indiana plant Official Action Indicated.
- The designation cites contamination and equipment failures at the plant.
- Scholar Rock and Regeneron face setbacks linked to the facility.
- Scholar Rock's spinal muscular atrophy treatment was recently rejected.
- Regeneron plans a new submission for its Eylea HD drug.
